EFFICACY AND SAFETY OF CHROMIUM AS A THERAPEUTIC INTERVENTION

铬作为治疗干预措施的功效和安全性

• 批准号: 7950787
• 负责人: DENNIS C MYNARCIK
• 金额: $ 1.6万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950787
• 关键词: Chromium; Chromium Picolinate; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Development; Diabetes Mellitus; Disease; Epidemic; Funding; Grant; Incidence; Institution; Insulin Resistance; Liver; Monitor; Morbidity - disease rate; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Patients; Pharmaceutical Preparations; Renal function; Research; Research Personnel; Resources; Safety; Source; Supplementation; Therapeutic Intervention; Toxic effect; United States National Institutes of Health; dietary supplements; improved; insulin sensitivity; mortality; oxidative damage; placebo controlled study; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The level of obesity has reached epidemic proportions [1] and contributes to increased mortality and morbidity [2]. Part of both mortality and morbidity arises from an increased incidence of insulin resistance and diabetes. However, it is possible to prevent progression to diabetes. A recent study has shown that when patients with insulin resistance were treated prior to the development of diabetes, there was a dramatic decrease in the number of subjects who went on to develop the disease [3]. Although several conventional drugs are effective in treating the insulin resistance associated with type 2 diabetes mellitus, the dietary supplement chromium picolinate has also been shown to improve insulin sensitivity in patients with type 2 diabetes mellitus[4]. Intriguingly, chromium is comparatively inexpensive and apparently well-tolerated [4]. Specific Aim 1 of this proposal will examine the safety and efficacy of supplemental chromium picolinate in the treatment of insulin resistance in obesity-related insulin resistance. We will assess improvements in insulin sensitivity in a placebo-controlled study of chromium supplementation over a two-month course of therapy. We will also assess the safety of chromium picolinate treatment. Parameters of liver, renal function and oxidative damage will be monitored for possible chromium-related toxicities.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 肥胖水平已达到流行比例[1]，并有助于增加死亡率和发病率[2]。 死亡率和发病率的一部分源于胰岛素抵抗和糖尿病的发生率增加。 但是，有可能防止糖尿病发展。 最近的一项研究表明，当胰岛素抵抗患者在糖尿病发生之前接受治疗时，继续发展该疾病的受试者数量会大大减少[3]。 尽管几种常规药物可有效治疗与2型糖尿病相关的胰岛素抵抗，但饮食补充剂chromium picolinate也已被证明可以改善2型糖尿病患者的胰岛素敏感性[4]。 有趣的是，铬相对便宜且明显耐受性良好[4]。 该提案的具体目的1将检查补充铬酸酯在肥胖相关胰岛素抵抗中胰岛素抵抗治疗胰岛素耐药性方面的安全性和功效。 在两个月的治疗过程中，我们将评估一项安慰剂对照铬补充的研究中胰岛素敏感性的改善。 我们还将评估Picolinate治疗铬的安全性。 将监测肝脏，肾功能和氧化损伤的参数，以获取可能与铬相关的毒性。